Theranostics 2018; 8(22):6352-6354. doi:10.7150/thno.31515

Editorial

Targeted nanoparticles for multimodal imaging of the receptor for advanced glycation end-products

Lindsey R. Drake, Peter J. H. Scott

Departments of Radiology and Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109, USA.

Abstract

The receptor for advanced glycation end-products (RAGE) is implicated in multiple disease states such as cancer, diabetes and neurodegenerative disorders, and RAGE inhibitors are being explored as potential new therapies in such cases. Despite the known role RAGE plays in these conditions, there remains an urgent need for a molecular imaging agent that can accurately quantify RAGE levels in vivo, aid in validation of RAGE as a biomarker and/or therapeutic target, and support development of new RAGE inhibitors. This editorial highlights a multimodal nanoparticle-based imaging agent targeted at RAGE that was recently developed by Konopka and colleagues (Theranostics 2018; 8(18):5012-5024. doi:10.7150/thno.24791).

Keywords: receptor for advanced glycation end-products, multimodal imaging, positron emission tomography.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Drake LR, Scott PJH. Targeted nanoparticles for multimodal imaging of the receptor for advanced glycation end-products. Theranostics 2018; 8(22):6352-6354. doi:10.7150/thno.31515. Available from http://www.thno.org/v08p6352.htm